While we acknowledge that these findings would benefit from validation with larger longitudinal datasets, GZMB has also demonstrated predictive utility for neoadjuvant avelumab in bladder cancer (Powles et al., 2019), and a prior report in ccRCC has shown TCF7+CD8+ T cell can be activated in vitro, and could maintain a progenitor-like state when located within antigen presentation niches (Jansen et al., 2019). Here, TCF7 is linked to urinary bladder cancer.